«Luteolin offers novel therapeutic regimen in rotenone-induced Parkinson disease via modulation of TNF-α/FXMRP/serotonin/tyrosine hydroxylase signaling pathway», NJPS, bd. 40, nr. 2, s. 251–262, des. 2025, doi: 10.54548/.